Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Sophia Drinis

Urology Beverly, MA Medical Doctor

NPI 1932175924 CMS profile 268848

85 Herrick St, Suite 200, Beverly, MA 01915

Open in the dashboard

General payments

$5,697

125 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

3 holdings reported · through program year 2022

Through program year 2022, Sophia Drinis of Beverly, MA is reported in the CMS Open Payments database as having received $5,697 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $318 15
2021 General $589 43
2020 General $1,185 28
2019 General $3,605 39
2021 Ownership $0 1
2020 Ownership $0 1
2019 Ownership $0 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sophia Drinis
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Sophia Drinis were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Sophia Drinis Urology median Middle half National median
2019 $3,605 $480 $147–$1,201 $163
2020 $1,185 $246 $87–$645 $114
2021 $589 $358 $111–$1,000 $132
2022 $318 $476 $143–$1,263 $149
2023 $0 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Coloplast Corp $4,306 54 payments
  2. Astellas Pharma US Inc $330 22 payments
  3. Boston Scientific Corporation $220 6 payments
  4. Pfizer Inc. $205 9 payments
  5. Axonics Modulation Technologies, Inc. $91 4 payments
  6. Endo Pharmaceuticals Inc. $87 6 payments
  7. Medtronic, Inc. $83 4 payments
  8. Urovant Sciences Inc $63 3 payments
  9. NeoTract Inc. $53 2 payments
  10. Allergan Inc. $41 2 payments
  11. Other $216 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Travel and Lodging $3,058 10 payments
  2. Food and Beverage $2,134 103 payments
  3. Education $504 12 payments
Products named General payments · program years 2019–2022
  1. TITAN $2,326 13 payments
  2. ALTIS $1,609 11 payments
  3. XTANDI $252 9 payments
  4. MYRBETRIQ $215 16 payments
  5. SpeediCath $161 13 payments
  6. PREMARIN $101 8 payments
  7. AVEED $87 6 payments
  8. XIAFLEX $87 6 payments
  9. EDEX $87 6 payments
  10. ESTRING $83 7 payments
  11. Other $1,014 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

887

Median for Urology: 1,053

Drug cost

$52,683

Median for Urology: $101,464

Branded share of claims

27.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 222 $14,284
Gemtesa Vibegron Brand 17 $12,912
Myrbetriq Mirabegron Brand 20 $9,824
Oxybutynin Chloride Er Oxybutynin Chloride Brand 128 $4,079
Tamsulosin Hcl Generic 153 $2,469
Methenamine Hippurate Generic 42 $2,168
Tolterodine Tartrate Er Tolterodine Tartrate Brand 24 $1,827
Trospium Chloride Generic 27 $1,576
Trimethoprim Generic 17 $1,246
Finasteride Generic 49 $1,173

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$133,309

Medicare's payments for the services billed

Medicare patients

358

Average age 76

Services billed

3,537

237 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 49%
Chronic kidney disease 36%
Ischemic heart disease 31%
Depression 30%
Atrial fibrillation 26%
Osteoporosis 26%
Diabetes 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record